ArticleJournal, genetic engineering & biotechnology2025
Biosynthesis, characterization, antibacterial, antibiofilm, and antioxidant activities of sodium nanoparticles from Escherichia coli metabolites.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study emphasizes the need for strategies to tackle multi-drug resistant pathogens by investigating the antibacterial, antibiofilm, and antioxidant properties of sodium nanoparticles (NaNPs) derived from metabolites of Escherichia coli. The configuration of the NaNPs was examined through X-ray diffraction (XRD), Transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), Photoluminescence (PL), and Ultraviolet-visible spectroscopy (UV-Vis). XRD and TEM analyses revealed that NaNPs possess a grain size around 125 nm, exhibiting a crystallinity of 63.45 % and a rod-shaped morphology. The UV-Vis revealed considerable absorbance at 280 nm, leading to an optical bandgap of 4.125 eV. To evaluate antibacterial and antibiofilm characteristics, clinical bacteria including Streptococcus pneumonia, Enterococcus faecium, Klebsiella pneumonia, and Salmonella Typhimurium were identified and examined for multidrug resistance using antibiogram testing. The antibacterial activity was assessed through agar well diffusion, minimum inhibitory and bactericidal concentrations (MIC and MBC) tests, and a time-kill assay. The antibiofilm effect was assessed by preventing biofilm formation and removing established biofilm assays. The antioxidant potential was assessed through the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay. Antibacterial results demonstrated a bactericidal effect on Enterococcus faecium and Salmonella Typhimurium (MBCs 0.0625 and 0.125 mg/mL, respectively). Inhibition zones ranged from 7.3 to 10.5 mm. NaNPs inhibited bacterial growth following 5 h of incubation. Antibiofilm results revealed an inhibitory effect on biofilm development (with an inhibition percentage of 62 %) and a minimal impact on biofilm elimination (showing a destruction percentage of 21 %). Antioxidant results showed a significant scavenging effect, with the percentage of radical scavenging reaching 23 %. The results suggest positive effects of the NaNPs in biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.